Carter J J, McLaughlin M L, Bern M M
Am J Med. 1983 Mar;74(3):523-5. doi: 10.1016/0002-9343(83)91002-1.
Bleomycin is a frequently used antitumor agent with adverse effects usually involving the lungs, skin, and bone marrow. An acute hyperpyrexic reaction has also been noted with this agent, usually after the initial injection. Thus a test dose is recommended before therapy is begun. A case of fulminant hyperpyrexia and death in a patient with lymphoma who had previously received multiple courses of bleomycin without prior hyperpyrexia is reported. Fever was associated with the patient's lymphoma and may have effectively reduced the patient's "margin" for tolerating the additional drug-induced pyrexia. It is suggested that attempts be made to lower fevers before therapy with this agent is initiated.
博来霉素是一种常用的抗肿瘤药物，其不良反应通常累及肺部、皮肤和骨髓。使用该药物时还曾观察到急性高热反应，通常在首次注射后出现。因此，建议在开始治疗前给予试验剂量。本文报告了1例淋巴瘤患者发生暴发性高热并死亡的病例，该患者此前接受过多个疗程的博来霉素治疗，之前未出现过高热。发热与患者的淋巴瘤有关，可能有效地降低了患者耐受额外药物性发热的“余地”。建议在开始使用该药物治疗前尝试降低体温。
